Chinese Journal of Dermatology ›› 2020, Vol. 53 ›› Issue (2): 147-151.doi: 10.35541/cjd.20190093
• Reviews • Previous Articles Next Articles
Chen Wenjuan1, Peng Chen1, Ding Yangfeng1, Shi Yuling2
Received:2018-12-07
Revised:2019-06-16
Online:2020-02-15
Published:2020-02-01
Contact:
Shi Yuling
E-mail:shiyuling1973@tongji.edu.cn
Supported by:Chen Wenjuan, Peng Chen, Ding Yangfeng, Shi Yuling. Psoriasis comorbidities[J]. Chinese Journal of Dermatology, 2020, 53(2): 147-151.doi:10.35541/cjd.20190093
| ［1］ | Reed WB, Becker SW, Rohde R, et al. Psoriasis and arthritis. Clinicopathologic study［J］. Arch Dermatol, 1961,83:541⁃548. |
| ［2］ | Alexander E, Pinto J, Pal GS, et al. Disease concomitance in psoriasis: a clinical study of 61 cases［J］. Indian J Dermatol Venereol Leprol, 2001,67（2）:66⁃68. |
| ［3］ | Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta⁃analysis［J］. J Invest Dermatol, 2013,133（10）:2340⁃2346. doi: 10.1038/jid.2013.149. |
| ［4］ | Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta⁃analysis of observational studies［J］. J Am Heart Assoc, 2013,2（2）:e000062. doi: 10.1161/JAHA.113.000062. |
| ［5］ | Shen J, Wong KT, Cheng IT, et al. Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease［J］. Ann Rheum Dis, 2017,76（7）:1237⁃1244. doi: 10.1136/annrheumdis⁃2016⁃210390. |
| ［6］ | Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis［J］. JAMA, 2006,296（14）:1735⁃1741. doi: 10.1001/jama.296.14.1735. |
| ［7］ | Picard D, Bénichou J, Sin C, et al. Increased prevalence of psoriasis in patients with coronary artery disease: results from a case⁃control study［J］. Br J Dermatol, 2014,171（3）:580⁃587. doi: 10.1111/bjd.13155. |
| ［8］ | Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China［J］. J Eur Acad Dermatol Venereol, 2009,23（11）:1311⁃1315. doi: 10.1111/ j.1468⁃3083.2009.03318.x. |
| ［9］ | Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink［J］. J Invest Dermatol, 2015,135（9）:2189⁃2197. doi: 10.1038/jid.2015.87. |
| ［10］ | Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study［J］. J Invest Dermatol, 2013,133（10）:2347⁃2354. doi: 10.1038/jid.2013.131. |
| ［11］ | Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis［J］. J Am Acad Dermatol, 2018,79（2）:345⁃352. doi: 10.1016/j.jaad.2018.02.040. |
| ［12］ | Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta⁃analysis of observational studies［J］. J Hypertens, 2013,31（3）:433⁃443. doi: 10.1097/HJH.0b013e32 835bcce1. |
| ［13］ | Kim HN, Han K, Song SW, et al. Hypertension and risk of psoriasis incidence: an 11⁃year nationwide population⁃based cohort study［J/OL］. PLoS One, 2018,13（8）:e0202854. doi: 10.1371/ journal.pone.0202854. |
| ［14］ | Wu S, Han J, Li WQ, et al. Hypertension, antihypertensive medication use, and risk of psoriasis［J］. JAMA Dermatol, 2014,150（9）:957⁃963. doi: 10.1001/jamadermatol.2013.9957. |
| ［15］ | Daudén E, Castañeda S, Suárez C, et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2013,27（11）:1387⁃1404. doi: 10.1111/jdv.12024. |
| ［16］ | Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co⁃morbid conditions［J］. J Invest Dermatol, 2010,130（7）:1785⁃1796. doi: 10.1038/jid.2010.103. |
| ［17］ | Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population⁃based cohort study［J］. J Am Acad Dermatol, 2014,70（4）:691⁃698. doi: 10.1016/j.jaad. 2013.11.023. |
| ［18］ | Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology［J］. J Am Acad Dermatol, 2017,76（3）:377⁃390. doi: 10.1016/j.jaad.2016.07.064. |
| ［19］ | Lønnberg AS, Skov L, Skytthe A, et al. Association of psoriasis with the risk for type 2 diabetes mellitus and obesity［J］. JAMA Dermatol, 2016,152（7）:761⁃767. doi: 10.1001/jamadermatol. 2015.6262. |
| ［20］ | Armstrong AW, Guérin A, Sundaram M, et al. Psoriasis and risk of diabetes⁃associated microvascular and macrovascular complications［J］. J Am Acad Dermatol, 2015,72（6）:968⁃977.e2. doi: 10.1016/j.jaad.2015.02.1095. |
| ［21］ | Gyldenløve M, Storgaard H, Holst JJ, et al. Patients with psoriasis are insulin resistant［J］. J Am Acad Dermatol, 2015,72（4）:599⁃605. doi: 10.1016/j.jaad.2015.01.004. |
| ［22］ | Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities［J］. An Bras Dermatol, 2015,90（1）:9⁃20. doi: 10.1590/abd1806⁃4841.20153038. |
| ［23］ | Jensen P, Skov L. Psoriasis and obesity［J］. Dermatology, 2016,232（6）:633⁃639. doi: 10.1159/000455840. |
| ［24］ | Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis［J］. J Am Acad Dermatol, 2006,55（5）:829⁃835. doi: 10.1016/j.jaad.2006. 08.040. |
| ［25］ | Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross⁃sectional study［J］. Dermatology, 2008,216（2）:152⁃155. doi: 10.1159/000111 512. |
| ［26］ | Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta⁃analysis［J］. Int J Obes （Lond）, 2015,39（8）:1197⁃1202. doi: 10.1038/ijo.2015.64. |
| ［27］ | Cao H. Adipocytokines in obesity and metabolic disease［J］. J Endocrinol, 2014,220（2）:T47⁃59. doi: 10.1530/JOE⁃13⁃0339. |
| ［28］ | Gómez R, Conde J, Scotece M, et al. What′s new in our understanding of the role of adipokines in rheumatic diseases?［J］. Nat Rev Rheumatol, 2011,7（9）:528⁃536. doi: 10.1038/nrrheum.2011.107. |
| ［29］ | Salahuddin T, Natarajan B, Playford MP, et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non⁃calcified burden of coronary atherosclerosis［J］. Eur Heart J, 2015,36（39）:2662⁃2665. doi: 10.1093/eurheartj/ehv339. |
| ［30］ | Kotronen A, Yki⁃Järvinen H. Fatty liver: a novel component of the metabolic syndrome［J］. Arterioscler Thromb Vasc Biol, 2008,28（1）:27⁃38. doi: 10.1161/ATVBAHA.107.147538. |
| ［31］ | Radtke MA, Mrowietz U, Feuerhahn J, et al. Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis［J］. J Dtsch Dermatol Ges, 2015,13（7）:674⁃690. doi: 10.1111/ddg.12643. |
| ［32］ | Rodríguez⁃Zúñiga M, García⁃Perdomo HA. Systematic review and meta⁃analysis of the association between psoriasis and metabolic syndrome［J］. J Am Acad Dermatol, 2017,77（4）:657⁃666.e8. doi: 10.1016/j.jaad.2017.04.1133. |
| ［33］ | Gui XY, Yu XL, Jin HZ, et al. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital⁃based cross⁃sectional study［J］. J Diabetes Investig, 2018,9（1）:39⁃43. doi: 10.1111/jdi.12663. |
| ［34］ | Chi C, Wang J, Chen Y, et al. Risk of incident chronic kidney disease and end⁃stage renal disease in patients with psoriasis: a nationwide population⁃based cohort study［J］. Value Health, 2015,18（7）:A415. doi: 10.1016/j.jval.2015.09.1004. |
| ［35］ | Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population⁃based study［J］. Br J Dermatol, 2011,165（5）:1037⁃1043. doi: 10.1111/j.1365⁃2133. 2011.10494.x. |
| ［36］ | Wan J, Wang S, Haynes K, et al. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study［J］. BMJ, 2013,347:f5961. doi: 10.1136/bmj.f5961. |
| ［37］ | Merola JF, Wu S, Han J, et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women［J］. Ann Rheum Dis, 2015,74（8）:1495⁃1500. doi: 10.1136/annrheumdis⁃2014⁃205212. |
| ［38］ | Gisondi P, Galvan A, Idolazzi L, et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities［J］. Front Med （Lausanne）, 2015,2:1. doi: 10.3389/fmed.2015.00001. |
| ［39］ | Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis［J］. J Invest Dermatol, 2006,126（10）:2194⁃2201. doi: 10.1038/sj.jid.5700410. |
| ［40］ | Geller S, Xu H, Lebwohl M, et al. Malignancy risk and recurrence with psoriasis and its treatments: a concise update［J］. Am J Clin Dermatol, 2018,19（3）:363⁃375. doi: 10.1007/s40257⁃017⁃0337⁃2. |
| ［41］ | Gu Y, Nordstrom BL. The risk of malignancy among biologic⁃naïve pediatric psoriasis patients: a retrospective cohort study in a US claims database［J］. J Am Acad Dermatol, 2017,77（2）:293⁃301.e1. doi: 10.1016/j.jaad.2017.03.044. |
| ［42］ | Wu JJ, Nguyen TU, Poon KY, et al. The association of psoriasis with autoimmune diseases［J］. J Am Acad Dermatol, 2012,67（5）:924⁃930. doi: 10.1016/j.jaad.2012.04.039. |
| ［43］ | Alidrisi HA, Al Hamdi K, Mansour AA. Is there any association between psoriasis and hashimoto′s thyroiditis?［J］. Cureus, 2019,11（3）:e4269. doi: 10.7759/cureus.4269. |
| ［44］ | Chi CC, Tung TH, Wang J, et al. Risk of uveitis among people with psoriasis: a nationwide cohort study［J］. JAMA Ophthalmol, 2017,135（5）:415⁃422. doi: 10.1001/jamaophthalmol.2017.0569. |
| ［45］ | Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2018,154（12）:1417⁃1423. doi: 10.1001/jamadermatol. 2018.3631. |
| ［46］ | Pietrzak D, Pietrzak A, Krasowska D, et al. Correction to: digestive system in psoriasis: an update［J］. Arch Dermatol Res, 2017,309（9）:695⁃696. doi: 10.1007/s00403⁃017⁃1788⁃2. |
| ［47］ | Galili E, Barzilai A, Shreberk⁃Hassidim R, et al. Neuropsychiatric comorbidity among adolescents with psoriasis［J］. Br J Dermatol, 2018,178（4）:910⁃916. doi: 10.1111/bjd.16031. |
| ［48］ | Aleem D, Tohid H. Pro⁃inflammatory cytokines, biomarkers, genetics and the immune system: a mechanistic approach of depression and psoriasis［J］. Rev Colomb Psiquiatr, 2018,47（3）:177⁃186. doi: 10.1016/j.rcp.2017.03.002. |
| ［49］ | Strober B, Gooderham M, de Jong E, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in psoriasis longitudinal assessment and registry （PSOLAR）［J］. J Am Acad Dermatol, 2018,78（1）:70⁃80. doi: 10.1016/j.jaad. 2017.08.051. |
| ［50］ | Christophers E. Periodontitis and risk of psoriasis: another comorbidity［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:757⁃758. doi: 10.1111/jdv.14249. |
| ［51］ | Papadavid E, Dalamaga M, Vlami K, et al. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital⁃based case⁃control study［J］. Sleep Breath, 2017,21（4）:949⁃958. doi: 10.1007/s11325⁃017⁃1507⁃4. |
| ［52］ | Chiang YY, Lin HW. Association between psoriasis and chronic obstructive pulmonary disease: a population⁃based study in Taiwan［J］. J Eur Acad Dermatol Venereol, 2012,26（1）:59⁃65. doi: 10.1111/j.1468⁃3083.2011.04009.x. |
| ［53］ | Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis［J］. Arthritis Res Ther, 2011,13（1）:R16. doi: 10.1186/ar3240. |
| ［54］ | Molina⁃Leyva A, Jiménez⁃Moleón JJ, Naranjo⁃Sintes R, et al. Sexual dysfunction in psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:649⁃655. doi: 10.1111/jdv. 12845. |
| ［55］ | Lebwohl M. Does treatment of psoriasis reduce cardiovascular comorbidities?［J］. J Invest Dermatol, 2017,137（8）:1612⁃1613. doi: 10.1016/j.jid.2017.06.001. |
| ［56］ | Shiga H, Fukuda S, Iijima K. Interleukin⁃17A inhibitor⁃induced Crohn′s disease/Behçet′s disease⁃like Lesions［J］. Inflamm Bowel Dis, 2017,23（6）:E38⁃38E39. doi: 10.1097/MIB.0000000 000001142. |
| ［57］ | Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon⁃like peptide⁃1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study［J］. Diabetes Res Clin Pract, 2019,150:167⁃173. doi: 10. 1016/j.diabres.2019.03.002. |
| [1] | Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848. |
| [2] | Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844. |
| [3] | Jing Ke, Wang Yuan, Li Suo, Feng Suying. Autoimmune subepidermal bullous diseases characterized by annular erythema and blisters: a retrospective analysis of 25 cases [J]. Chinese Journal of Dermatology, 2023, 56(9): 832-838. |
| [4] | Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802. |
| [5] | Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692. |
| [6] | Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705. |
| [7] | Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650. |
| [8] | Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625. |
| [9] | Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517. |
| [10] | China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401. |
| [11] | Jin Liping, Zhu Wu, Lu Yan, Liu Panpan, Tan Minjia, Wang Ying, Yang Jing, Xu Licong, Hu Kun, Kuang Yehong. Dietary intervention for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(4): 357-360. |
| [12] | Lian Panpan, Liu Jun, Su Zhonglan, Wang Hongwei. Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes [J]. Chinese Journal of Dermatology, 2023, 56(4): 365-368. |
| [13] | Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322. |
| [14] | Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203. |
| [15] | Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251. |
|
